Revolutionising Health Care: Can Microbiome Modulators Unlock Gut Health Potential?

Key Takeaways:

• Carbiotix is a pre-clinical stage therapeutics company focusing on low-cost gut health testing and microbiome modulators
• Founded in 2014 and based on four years of research, they have won numerous awards for their second-generation soluble fiber AXOS
• The company is working to unlock the potential of the gut microbiome to address a range of chronic and metabolic diseases.
• Carbiotix’s future lies in leveraging data from its gut health testing, which will lead to the creation of microbiome modulators.

There’s a revolution underway in healthcare, and it’s all centered around the gut. From being intangible and largely ignored, the gut microbiome has emerged as a major focus in our understanding of health and disease. Leading the charge in this newfound territory is Carbiotix, an award-winning pre-clinical stage therapeutics company based in Lund, Sweden. With their vision focused squarely on low-cost gut health testing and the development of microbiome modulators, Carbiotix is at the forefront of this burgeoning industry.

Founded in 2014 by Kristofer Cook and Peter Falck, Carbiotix has been building on four years of research through the Department of Biotechnology at Lund University and the Antidiabetic Food Centre (AFC). An early validation of their work came in 2015, when their second-generation soluble fiber AXOS (a key ingredient in the modulation of the gut microbiome) was selected as a top new ingredient by the Nutrition Capital Network (NCN) in Europe and the US.

What sets Carbiotix apart, beyond their commitment to affordable testing, is the comprehensive approach they’re taking to gut microbiome health. Recognising that gut health is implicated in a range of chronic and metabolic diseases, the company is developing microbiome modulators to help people strengthen their gut bacteria, thereby improving their overall health. Their platform, launched in 2018, marked the start of a significant gut health study involving 600 participants.

Further, Carbiotix is harnessing data generated from this testing platform to not only improve our understanding of gut microbiome health but also drive the development of their therapeutics. This model of generating data through health testing and using that data to boost therapeutic development activities truly sets them apart. Furthermore, their long-term strategy involves the creation of microbiome modulators based on a combination of proprietary soluble fiber, isolated strains, and novel delivery mechanisms that speaks to their advanced and innovative approach.

Looking to the future, Carbiotix is set to continue disrupting the healthcare industry with their cutting-edge technologies and innovative approach. The potential of their work is immense – offering hope for effective interventions against a host of diseases and contributing towards a healthier future. Their research could redefine our understanding of health and disease, and in doing so, radically alter the way we approach healthcare.

For more on this inspiring company and the exciting work they’re doing, be sure to check them out on their website and follow them on Twitter, Facebook and LinkedIn. The future of healthcare is unfolding, and Carbiotix is leading the way.